Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Arm VIIA: 500 mg/m2 BOLD-100 combined with FOLFOX ± Bevacizumab; Arm VIIB: 625 mg/m2 BOLD-100 combined with FOLFOX ± Bevacizumab; Arm VIIC: FOLFOX ± Bevacizumab alone”In the company’s words, NCT04421820 on ClinicalTrials.gov
- Main trialPhase 1/2
- “BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX ± Bevacizumab chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase. This study now includes as a treatment intervention the SOC combination FOLFOX ± Bevacizumab, if indicated.”In the company’s words, NCT04421820 on ClinicalTrials.gov
Other drugs for Colorectal Cancer
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up1
- 1 Jul 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 1 Jul 2027 | BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026